Elucidation of the Genetic Cause in Dutch Limb Girdle Muscular Dystrophy Families: A 27-Year's Journey

Autor: L. ten Dam, Anneke J. van der Kooi, Ieke B. Ginjaar, Hermine A. van Duyvenvoorde, M. de Visser, Silvana van Koningsbruggen
Přispěvatelé: Neurology, ANS - Neuroinfection & -inflammation, Human Genetics, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, EURO-NMD
Rok vydání: 2021
Předmět:
Adult
Male
Adolescent
Ubiquitin-Protein Ligases
Muscle Proteins
Mitochondrial Membrane Transport Proteins
Muscular Dystrophies
whole exome sequencing
Tripartite Motif Proteins
SGCG
symbols.namesake
Limb girdle muscular dystrophy
Young Adult
gene panel
Exome Sequencing
medicine
Sarcoglycanopathies
Humans
Genetic Testing
Child
sanger sequencing
Cation Transport Proteins
Dysferlin
Exome sequencing
Genetic testing
SGCA
Netherlands
Genetics
Sanger sequencing
medicine.diagnostic_test
business.industry
Calpain
Calcium-Binding Proteins
Dystrophy
High-Throughput Nucleotide Sequencing
Sequence Analysis
DNA

Middle Aged
medicine.disease
Sarcoglycanopathy
Phenotype
Neurology
Muscular Dystrophies
Limb-Girdle

Mutation
symbols
Female
Neurology (clinical)
business
Limb-girdle muscular dystrophy
Transcription Factors
Zdroj: Journal of neuromuscular diseases, 8(2), 261-272. IOS Press
JOURNAL OF NEUROMUSCULAR DISEASES
JOURNAL OF NEUROMUSCULAR DISEASES, 8(2), 261-272. IOS PRESS
ISSN: 2214-3602
2214-3599
Popis: Background: A Dutch cohort of 105 carefully selected limb girdle muscular dystrophy (LGMD) patients from 68 families has been subject to genetic testing over the last 20 years. After subsequent targeted gene analysis around two thirds (45/68) of the families had received a genetic diagnosis in 2013. Objective: To describe the results of further genetic testing in the remaining undiagnosed limb girdle muscular dystrophy families in this cohort. Methods: In the families of the cohort for whom no genetic diagnosis was established (n = 23) further testing using Sanger sequencing, next generation sequencing with gene panel analysis or whole-exome sequencing was performed. In one case DNA analysis for facioscapulohumeral dystrophy type 1 was carried out. Results: In eight families no additional genetic tests could be performed. In 12 of the remaining 15 families in which additional testing could be performed a genetic diagnosis was established: two LGMDR1 calpain3-related families with CAPN3 mutations, one LGMDR2 dysferlin-related family with DYSF mutations, three sarcoglycanopathy families (LGMDR3-5 α-, β- and γ-sarcoglycan-related) with SGCA/SGCB/SGCG mutations, one LGMDR8 TRIM 32-related family with TRIM32 mutations, two LGMDR19 GMPPB-related families with GMPPB mutations, one family with MICU1-related myopathy, one family with FLNC-related myopathy and one family with facioscapulohumeral dystrophy type 1. At this moment a genetic diagnosis has been made in 57 of the 60 families of which DNA was available (95%). Conclusion: A genetic diagnosis is obtained in 95% of the families of the original Dutch LGMD cohort of which DNA was available.
Databáze: OpenAIRE